Envestnet Asset Management Inc. Sells 4,908 Shares of Chemed Corporation $CHE

Envestnet Asset Management Inc. decreased its position in Chemed Corporation (NYSE:CHE) by 6.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 75,215 shares of the company’s stock after selling 4,908 shares during the period. Envestnet Asset Management Inc. owned 0.51% of Chemed worth $36,624,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in CHE. HM Payson & Co. bought a new position in Chemed in the first quarter valued at about $30,000. SVB Wealth LLC bought a new position in Chemed in the first quarter valued at about $30,000. WPG Advisers LLC acquired a new position in Chemed in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. lifted its holdings in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares during the period. Finally, Zions Bancorporation National Association UT acquired a new position in Chemed in the first quarter valued at approximately $68,000. Institutional investors own 95.85% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CHE. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday. Bank of America dropped their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Finally, Royal Bank Of Canada dropped their price objective on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $578.50.

Chemed Stock Performance

Shares of NYSE CHE opened at $431.00 on Friday. The stock has a market cap of $6.28 billion, a P/E ratio of 22.79, a P/E/G ratio of 2.69 and a beta of 0.43. The firm has a 50 day moving average price of $447.69 and a 200 day moving average price of $492.79. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). The business had revenue of $624.90 million for the quarter, compared to the consensus estimate of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The business’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Analysts predict that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemed news, Director George J. Walsh III bought 200 shares of Chemed stock in a transaction on Monday, August 4th. The shares were purchased at an average cost of $417.10 per share, for a total transaction of $83,420.00. Following the completion of the acquisition, the director owned 3,523 shares in the company, valued at approximately $1,469,443.30. The trade was a 6.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Patrick P. Grace sold 150 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director owned 3,397 shares in the company, valued at $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 13,162 shares of company stock valued at $5,677,511. Insiders own 3.29% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.